NO20064515L - Farmasoytisk preparat med kontrollert frigivelse av tolperison for oral administrering - Google Patents

Farmasoytisk preparat med kontrollert frigivelse av tolperison for oral administrering

Info

Publication number
NO20064515L
NO20064515L NO20064515A NO20064515A NO20064515L NO 20064515 L NO20064515 L NO 20064515L NO 20064515 A NO20064515 A NO 20064515A NO 20064515 A NO20064515 A NO 20064515A NO 20064515 L NO20064515 L NO 20064515L
Authority
NO
Norway
Prior art keywords
tolperison
oral administration
active substance
controlled release
pharmaceutical preparation
Prior art date
Application number
NO20064515A
Other languages
English (en)
Inventor
Eberhard Pirich
Werner Frantsits
Angelika Bodenteich
Josef Bockmann
Original Assignee
Sanochemia Pharmazeutika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag filed Critical Sanochemia Pharmazeutika Ag
Publication of NO20064515L publication Critical patent/NO20064515L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrevede tolpersisonholdige farmasøytiske preparat med kontrollerbar fiigivelse av aktivt stoff for oral administrering, hvor det aktive stoffet tolperison og/eller et farmasøytisk salt derav er iimstøpt i et farmasøytisk kompatibelt materiale. Ved å velge farmasøytisk kompatible materialer ved fremstilling av følgelig i belegget av en tablett eller et kom kan en spesifikk fiigivelse av aktivt stoff justeres som tilpasses til den spesielle genotypen ved metaboliseringen av tolperison. Samtidig, som et resultat av den meget uniforme og vedvarende fiigivelsen av tolperison kan in-vivo inversjonen av enantiomerisk ren tolperison som er kjent innen teknikken justeres til fordel for R(-) tolperison som er fremtredende innen muskelrelakserende terapi.
NO20064515A 2004-03-05 2006-10-04 Farmasoytisk preparat med kontrollert frigivelse av tolperison for oral administrering NO20064515L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0038604A AT500144A1 (de) 2004-03-05 2004-03-05 Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
PCT/EP2005/002379 WO2005094825A1 (en) 2004-03-05 2005-03-07 Controlled release pharmaceutical composition of tolperisone for oral administration

Publications (1)

Publication Number Publication Date
NO20064515L true NO20064515L (no) 2006-10-04

Family

ID=34891569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064515A NO20064515L (no) 2004-03-05 2006-10-04 Farmasoytisk preparat med kontrollert frigivelse av tolperison for oral administrering

Country Status (11)

Country Link
US (3) US20050196451A1 (no)
EP (1) EP1737455A1 (no)
JP (1) JP2007526277A (no)
CN (1) CN1929839A (no)
AT (1) AT500144A1 (no)
AU (1) AU2005229519A1 (no)
CA (1) CA2552542A1 (no)
MX (1) MXPA06010072A (no)
NO (1) NO20064515L (no)
RU (1) RU2006135124A (no)
WO (2) WO2005084676A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
AT500999A1 (de) * 2004-11-11 2006-05-15 Sanochemia Pharmazeutika Ag Tolperison enthaltendes veterinärmedizinisches präparat zur oralen verabreichung bei der behandlung von säugetieren, wie hunden mit degenerativen, spinalen symptomen
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
MX2008013437A (es) * 2006-04-20 2009-03-06 Sanochemia Pharmazeutika Ag Metodo para administrar tolperisona.
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
HUP0700485A3 (en) 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
GEP20135986B (en) 2009-03-09 2013-12-10 Shashikant Prabhudas Kurani Novel sustained release composition of compounds selected from class of centrally acting muscle relaxants
EP2591773A4 (en) 2010-07-06 2014-11-26 Navipharm Co Ltd TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
KR101156054B1 (ko) * 2011-09-05 2012-06-20 주식회사 네비팜 안정한 에페리손 함유 서방성 의약조성물
CN107375254A (zh) * 2017-08-30 2017-11-24 李炜 一种用于治疗糖尿病的外用贴膏及其使用方法
TR201818859A2 (tr) * 2018-12-07 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
JPH0637389B2 (ja) * 1986-12-26 1994-05-18 北陸製薬株式会社 頻尿治療剤
JPH0720866B2 (ja) * 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
DE69428707T2 (de) * 1993-08-20 2002-07-11 Nippon Shinyaku Co Ltd Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
EP1101490B1 (en) * 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
WO2000024423A1 (fr) * 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Particules a liberation prolongee
JP2000128774A (ja) * 1998-10-26 2000-05-09 Tanabe Seiyaku Co Ltd 薬物を含有する球形微粒子の製法
AT409083B (de) * 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US7220430B2 (en) * 2000-01-27 2007-05-22 Tanabe Seiyaku Co., Ltd. Sustained-release preparation and process for producing the same
KR100866820B1 (ko) * 2000-07-13 2008-11-04 다케다 야쿠힌 고교 가부시키가이샤 지질 풍부 플라크 퇴축제
CA2363902C (en) * 2000-12-07 2005-07-26 Warner-Lambert Company Process and system for controlled-release drug delivery
KR100507946B1 (ko) * 2001-01-31 2005-08-17 룀 게엠베하 운트 콤파니 카게 상이하게 피복된 펠렛 형태를 두 가지 이상 포함하는 다중 입상형 약제
US7192608B2 (en) * 2001-03-07 2007-03-20 Sumitomo Pharmaceuticals Company Limited Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
US20060004050A1 (en) * 2004-07-02 2006-01-05 Speicher Brian T Compositions and methods for the prevention or treatment of pain and other nervous system disorders

Also Published As

Publication number Publication date
CN1929839A (zh) 2007-03-14
JP2007526277A (ja) 2007-09-13
US20050196451A1 (en) 2005-09-08
WO2005094825A1 (en) 2005-10-13
EP1737455A1 (en) 2007-01-03
CA2552542A1 (en) 2005-10-13
US20080226713A1 (en) 2008-09-18
US20060198888A1 (en) 2006-09-07
WO2005084676A1 (de) 2005-09-15
AT500144A1 (de) 2005-11-15
RU2006135124A (ru) 2008-04-10
MXPA06010072A (es) 2007-01-26
AU2005229519A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
NO20064515L (no) Farmasoytisk preparat med kontrollert frigivelse av tolperison for oral administrering
NO2014028I2 (no) Glukopyranosyl-substituerte benzenderivater, fremgangsmåte for fremstilling av disse, fysiologisk akseptable salter av slike forbindelser, medikamenter inneholdende slike forbindelser og kombinasjoner med andre aktive substanser samt deresanvendelse for fremstilling av medikamenter for behandling av sykdom
WO2008101907A3 (en) N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP2009517473A5 (no)
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
DK1791532T3 (da) Sammensætning i mikropelletform med styret afgivelse af fysiologisk aktive stoffer, fremgangsmåde til deres fremstilling og anvendelse i den zootekniske sektor
JP2007527914A5 (no)
NO20073928L (no) Stabilt partikkelformig legemiddel med solifenacin eller salt av dette
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
IL189546A0 (en) Therapy for the treatment of disease
EA200800198A1 (ru) Способы предупреждения и лечения метаболических нарушений и новые производные пиразол-о-гликозида
MX2009008228A (es) N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide.
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
WO2005076979A3 (en) Diagnosis and therapeutics for cancer
HRP20180327T1 (hr) Sredstva za uporabu u slučaju intolerancije na fruktozu
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
CL2007002196A1 (es) Compuestos heterociclicos nitrogenados, moduladores de la actividad del receptor de quimioquina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, obesidad, sindrome metabolico y dolor.
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2001080824A3 (en) Dual mechanism timed release dosage forms for low dose drugs
DK2024387T3 (da) Peptidsubstans, der forstærker kapillær modstand, farmaceutisk komposition med dens base og fremgangsmåde til applicering deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application